Life Sciences & Healthcare | Venari Partners

‘I’ve been doing this for a long, long time. I think it’s a very rewarding thing to do.’ This episode of the Venari Podcast’s Talking Radiopharma series saw Matthew Palmer speak to Ariceum Therapeutics CEO Manfred Ruediger. A serial biotech entrepreneur, Manfred has worked in executive functions in biotech for almost 25 years. Ariceum’s development of novel targeted radiopharmaceuticals for cancer treatment – as well as Manfred’s considerable experience building out companies – certainly offered plenty of scope for discussion. Tune in to hear more about what Ariceum do differently, plus Manfred’s thoughts on team building and his advice for the radiopharmaceutical innovators of tomorrow! Our thanks to the Ariceum CEO and his team for this fascinating podcast. Listen on your favourite podcast platform here: https://lnkd.in/ehu3ZAxW #lifesciences #healthcare #radiopharma #insights #leadership

The US market has long been considered the ‘Holy Grail’ for European HealthTech companies. After Series A, stateside expansion is often the next step – but despite the great opportunities the US offers, without the right preparation and resources European businesses that are successfully domestically can struggle across the pond. I’ve helped more than a few digital health companies scale from Europe to the US, so it seemed logical to put together a mini guide for businesses thinking about crossing the Atlantic. Read on to hear about topics such as value proposition, patient journey, and the FDA approval process, among others! #healthtech #lifesciences #digitalhealth #healthcare #insight #talent

Less than one week to go until the The Digital Health Cocktail Hour (DHCH) on Wednesday 29th May! The DHCH is all about creating a casual, friendly environment where early stage healthcare & life science start-ups can connect with clinicians, researchers, industry leaders, and investors to identify opportunities to get their solutions delivering scaled clinical impact, faster. The event will be hosted at the London Institute of Healthcare Engineering, at St. Thomas’ Campus. If you are in London and are interested in joining, click the link below to register: https://bit.ly/49V5F1m

Join us for an evening of relaxed networking and fruitful connections at the Digital Health Cocktail Hour! Our aim is simple: to provide a welcoming space where early-stage healthcare and life science start-ups can mingle with clinicians, researchers, industry leaders, and investors. Save the date: May 29th, when we'll convene at the London Institute of Healthcare Engineering, located at St. Thomas’ Campus. A heartfelt thank you to our current hosts—AWS Startups, Cambridge Angels, Octopus Ventures, and Venari Partners—and stay tuned for more to come! Sign up for the May 29th event in London here: https://bit.ly/49V5F1m AWS Startups Venari Partners | Executive Search & Advisory Services Cambridge Angels Octopus Ventures Alex Merwin Guy Spigelman Nicolas Huber Sebastien Shamik J Parekh Hugo Michelle Tempest Abhijit Kulkarni Shahar Vigdor

✍ Nominations for this year’s Venari Partners Challenge are now open! Our award-winning CSR campaign is back for another instalment. This September, we’re sending especially deserving participants on a fully funded adventure to the stunning Norwegian fjords. Trekkers will raise money for suicide prevention charity Campaign Against Living Miserably (CALM), our official fundraising partner for the initiative. Participants will be selected via our open nominations process, which is free to enter. We want to provide a boost to people who have faced significant challenges in their lives – so if you can think of someone you’d like to put forward, we’d love to hear from you. You’re more than welcome to nominate yourself, of course! The nominations window is open from today until 1 July - click the link below now! #VPchallenge #charity #csr #fundraise

🏞 Imagine an all-expenses-paid hiking and kayaking adventure through the stunning Norwegian fjords. Well, what if you could go on such a trip, and raise money for charity in the process? With the Venari Partners Challenge, you can do just that! This September, our award-winning charity venture – which has been recognised by the Better Society Awards, Communitas, and the International CSR Excellence Awards – returns for another instalment. We want to give especially deserving people who have faced challenging personal circumstances a chance to undertake an incredible expedition through a beautiful UNESCO World Heritage Site. Participants will hike, camp, and kayak in Norway while fundraising for suicide prevention charity Campaign Against Living Miserably (CALM), our official charity partner for the Challenge. Sounds appealing, right? Nominations are open to all from 1 May. Be sure to check our website and social media for further developments. Thank you – and looking forward to receiving your nominations! #fundraise #adventure #VPchallenge #charity #csr #nominate

🧬 The LSX - partnering for Life Science eXecutives World Congress is next week! If you would like to talk to one of our Consultants about our services and solutions, come find us at stand 1! #lsx #lifesciences #biotech #healthtech #medtech

Nuclear medicine needs young talent – so what’s the best way to attract new candidates to the field? Ken Herrmann and Valentina Ambrosini, from Essen University Hospital and the University of Bologna respectively, recently caught my attention by co-authoring an article on this subject. I was delighted to invite them to speak on the Venari Podcast’s Talking Radiopharma series to hear more. Tune in to hear from Ken and Valentina on the results of their survey on what young people in the radiopharma space want, ways of making this fascinating subject more accessible, and what the nuclear medicine talent of tomorrow should do to succeed in the field. Many thanks to Ken and Valentina for joining me! #radiopharma #talent #lilfesciences #healthcare #nuclearmedicine

At a recent panel, Michael Greeley of Flare Capital Partners and Robbie Freeman from Mount Sinai highlighted key characteristics that distinguish successful digital health start-ups in today's market.

What is the current state of play in #radiotheranostics and what are the opportunities and challenges to watch out for? This article, written by Akram Al-Ibraheem MD, FRCP, FEBNN, FANNB, Richard Zimmermann, Ahmed Abdlkadir and Ken Herrmann offers a timely answer. My key takeaways: ➡ The Global nuclear medicine market is expected to attain a value of $39B by 2032, with a specific growth of 24% annually due to therapeutic radiopharmaceuticals. ➡ More big pharma players are likely to enter the field, driving further investment and opening opportunities for promising combination therapy approaches, ultimately benefiting patients. However, this will also undoubtedly lead to further consolidation of the sector. ➡ Despite promising growth prospects, risks persist. Negative clinical results caused by adverse events due to “dose-dependent chronic effects on nontarget organs” as well as the challenges posed by the handling and timely transport of radioactive materials. Resource limitations and cost of care, particularly in low-middle income countries may limit clinical uptake. ➡ The scarcity of specialised talent stands as another potential barrier to growth. The pace of clinical advancements, coupled with regulatory approvals for novel radiopharmaceutical interventions, may outpace the capacity of both industry and healthcare systems to adequately train and recruit staff for production, distribution, and administration of these therapies. ➡ New and improved radiotheranostics will be discovered, aided by advances in radiochemistry and radiopharmacy and they will be applied to more cancer indications, more effectively. They will also be used earlier in the patient care journey, reducing the adverse off-target effects that older radiotherapies imposed, ultimately improving patient outcomes and survivability rates.